Drug Trial Radar · NCT06289673
Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
850
Planned (sponsor's estimate)
Start
Dec 26, 2024
Primary completion
May 2034
Study completion May 2039
Sponsor
- Lead sponsor
- St. Jude Children's Research HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 4, 2024
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 1 year, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this study is to provide sufficient therapy during the time a patients' B-cell Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LLy) risk category is being determined. The term "risk" refers to the chance of the ALL or LLy coming back after treatment. Primary Objectives * To provide sufficient therapy to enable testing of newly diagnosed acute lymphoblastic leukemia/lymphoma and mixed phenotype acute leukemia/lymphoma tumor samples to determine eligibility and appropriate risk stratification for SJALL therapeutic studies. * To develop a central database of genomic and clinical findings. Secondary Objectives * To assess event free and overall survival data of patients enrolled on this study.
Conditions
- Acute Lymphoblastic Leukemia
- Lymphoblastic Lymphoma
- Mixed Phenotype Acute Leukemia
Interventions
DexamethasoneDrug
Per mouth (PO) or intravenously (IV) once on Day 1 and PO or IV divided BID (every 12 hours) days 2-7
VincristineDrug
Intravenously (IV) for 1 dose on Day 1 or 2
DaunorubicinDrug
Intravenously (IV) for 1 dose on Day 2 or 3 (T-ALL/ T-LLy/ MPAL only)
Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine)Drug
Intrathecal (Age adjusted) for 1 dose on Day 4 or 5 or 6
MethotrexateDrug
Given IT as part of Intrathecal triple therapy.
CytarabineDrug
Given IT as part of Intrathecal triple therapy.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Sufficient phenotypic and/or genomic data necessary for therapeutic protocol assignment by Day 8 (completion of INITIALL therapy).Time frame: 1 week from study entry
- Complete data within the INITIALL databaseTime frame: 3 months, 1 year, 3, 5 years from study entry
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Rady Children's Hospital
San Diego, California · Recruiting
Our Lady of the Lakes Regional Medical Center
Baton Rouge, Louisiana · Recruiting
Novant Health Presbyterian Hemby Children's Hospital
Charlotte, North Carolina · Recruiting
Saint Francis Children's Hospital
Tulsa, Oklahoma · Recruiting
St. Jude Children's Research Hospital
Memphis, Tennessee · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.